Inhibrx Biosciences, Inc.

NasdaqGS:INBX Stock Report

Market Cap: US$211.3m

Inhibrx Biosciences Management

Management criteria checks 0/4

Inhibrx Biosciences' CEO is Mark Lappe, appointed in May 2024, has a tenure of less than a year. directly owns 6.39% of the company’s shares, worth $13.51M. The average tenure of the management team and the board of directors is 0.9 years and 0.9 years respectively.

Key information

Mark Lappe

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership6.4%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates


CEO

Mark Lappe (57 yo)

less than a year

Tenure

Mr. Mark Paul Lappe serves as Chief Executive Officer, President and Chairperson of the board of directors at Inhibrx Biosciences, Inc. since May 30, 2024. He co-founded Efficacy Capital Limited in 2004 se...


Leadership Team

NamePositionTenureCompensationOwnership
Mark Lappe
Founderless than a yearno data6.39%
$ 13.5m
Brendan Eckelman
Founderless than a yearno data3.55%
$ 7.5m
Kelly Deck
Executive VPless than a yearno datano data
Bonne Adams
Vice President of Operationsless than a yearno datano data
Ashraf Amanullah
Executive VP & Chief Technical Operations Officerless than a yearno datano data
Leah Pollema
VP & General Counselless than a yearno datano data
Josep Garcia
Executive VP & Chief Clinical Development Officerless than a yearno datano data
David Matly
Executive VP and Chief Commercial & Business Development Officerless than a yearno datano data
Carlos Bais
Executive Vice President of Translational Sciencesless than a yearno datano data

0.9yrs

Average Tenure

47yo

Average Age

Experienced Management: INBX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Mark Lappe
Founderless than a yearno data6.39%
$ 13.5m
Douglas Forsyth
Independent Directorless than a yearno data1.55%
$ 3.3m
Kimberly Manhard
Independent Directorless than a yearno data0.069%
$ 146.0k
John Kayyem
Independent Directorless than a yearno data7.94%
$ 16.8m
Robert Sandhaus
Member of INBRX-101 Scientific Advisory Boardless than a yearno datano data
James Stoller
Member of INBRX-101 Scientific Advisory Boardless than a yearno datano data
Kristiina Vuori
Independent Directorless than a yearno data0.14%
$ 298.5k
Igor Barjaktarevic
Member of INBRX-101 Scientific Advisory Boardless than a yearno datano data
Mark Brantly
Member of INBRX-101 Scientific Advisory Boardless than a yearno datano data
Kenneth Chapman
Member of INBRX-101 Scientific Advisory Boardless than a yearno datano data
Noel McElvaney
Member of INBRX-101 Scientific Advisory Boardless than a yearno datano data

0.9yrs

Average Tenure

57yo

Average Age

Experienced Board: INBX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:15
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Inhibrx Biosciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution